公开(公告)号：WO2015028888A2

公开(公告)日：2015-03-05

申请号：PCT/IB2014/002527

申请日：2014-08-25

Applicant: SENTINEXT THERAPEUTICS SDN BHD

Inventor： CARDOSA, Mary, Jane ,  MONATH, Thomas

IPC: A61K39/42

CPC classification number: C07K16/1009 ,  A61K39/12 ,  A61K2039/505 ,  A61K2039/5258 ,  C12N2710/14143 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32623 ,  C12N2770/32634 ,  C12N2840/203 ,  Y02A50/466

Abstract: The invention provides materials and methods for a pharmaceutical composition comprising a polyclonal antibody preparation or a monoclonal antibody preparation or an antibody fragment preparation with or without a drug to prevent the infection of, or treat an infection of a subject by a Human Enterovirus, including, a Human Enterovirus responsible for foot, hand and mouth disease. The pharmaceutical composition includes a polyclonal antibody preparation or a monoclonal antibody preparation or an antibody fragment preparation to protect against or treat an infection by a Human Enterovirus, including, a Human Enterovirus responsible for foot, hand and mouth disease. The invention further provides for a method to use the pharmaceutical composition to protect against or treat an infection by a Human Enterovirus, including, a Human Enterovirus responsible for foot, hand and mouth disease as well as kits to do the same.

Abstract translation: 本发明提供了包含多克隆抗体制剂或单克隆抗体制剂或具有或不具有药物以防止人肠道病毒感染或治疗受试者感染的抗体片段制备物的药物组合物的材料和方法， 一种负责脚部，口腔疾病的人肠道病毒。 该药物组合物包括多克隆抗体制备物或单克隆抗体制剂或抗人体肠道病毒感染的抗体片段制备物，包括负责脚部，口腔疾病的人肠道病毒。 本发明进一步提供了使用该药物组合物来防止或治疗人肠道病毒感染的方法，所述人肠病毒包括负责足部，手部和口腔疾病的人肠道病毒以及进行相同操作的试剂盒。

公开(公告)号：WO2013098655A2

公开(公告)日：2013-07-04

申请号：PCT/IB2012003114

申请日：2012-11-01

Applicant: SENTINEXT THERAPEUTICS SDN BHD

Inventor： CARDOSA MARY JANE ,  JAMILUDDIN MOHAMAD FAKRUDDIN ,  HAMID SHARIFAH BINTI

IPC: A61K39/125

CPC classification number: A61K39/125 ,  A61K39/12 ,  A61K39/13 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/14043 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32351 ,  C12N2770/32371 ,  C12N2770/32634

Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.

Abstract translation: 本发明提供了用于产生衍生自小核糖核酸病毒科病毒家族成员的免疫活性抗原的材料和方法。 本发明的小核糖核酸病毒抗原可以是用于在治疗性治疗中施用于受试者的疫苗或用于预防小RNA病毒感染的形式。 本发明的小核糖核酸病毒抗原可以是用于疫苗的免疫原性组合物的形式，其用于预防肠道病毒感染。 本发明还包括包含人肠道病毒A，人肠道病毒B，人肠病毒C，人肠道病毒D抗原及其在疫苗中用于预防肠道病毒感染的应用的免疫原性组合物。

公开(公告)号：WO2018066999A2

公开(公告)日：2018-04-12

申请号：PCT/MY2017/050059

申请日：2017-09-21

Applicant: SENTINEXT THERAPEUTICS SDN BHD

Inventor： CARDOSA, Mary Jane

IPC: A61K39/125

CPC classification number: A61K39/125 ,  A61K39/13 ,  A61K39/135 ,  A61K2039/5258 ,  A61K2039/575 ,  A61K2039/70 ,  C12N2710/00034 ,  C12N2770/32322 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32371 ,  Y02A50/466

Abstract: The invention provides chimeric Enterovirus virus-like particles (VLPs) for protection and/or treatment against infection by more than one Enterovirus . More specifically, the present invention provides chimeric EV-A71 virus-like particles displaying CV-A16 VP1 polypeptides and at the same time maintaining important neutralizing antibody epitopes of EV-A71 itself. More specifically, the present invention provides chimeric CV-A16 virus-like particles displaying EV-A71 VP1 polypeptides. Thus, the present invention provides a bivalent vaccine comprising the chimeric virus-like particles which elicit an immune response and/or neutralizing antibody response to both EV-A71 and CVA-16 for the treatment of Hand, Foot and Mouth Disease.

Abstract translation: 本发明提供了用于防止和/或治疗超过一种肠道病毒的感染的嵌合型肠病毒样颗粒（VLP）。 更具体地说，本发明提供了展示CV-A16 VP1多肽的嵌合EV-A71病毒样颗粒，同时维持了EV-A71本身的重要中和抗体表位。 更具体地说，本发明提供了展示EV-A71 VP1多肽的嵌合CV-A16病毒样颗粒。 因此，本发明提供了包含嵌合病毒样颗粒的二价疫苗，所述嵌合病毒样颗粒对EV-A71和CVA-16两者引发免疫应答和/或中和抗体应答以治疗手足口病。

公开(公告)号：WO2006080682A1

公开(公告)日：2006-08-03

申请号：PCT/KR2005/003274

申请日：2005-10-05

Applicant: REPUBLIC OF KOREA ,  CHOI, Kang Seuk ,  KO, Young Joon ,  NAH, Jin Ju ,  JO, Nam In

Inventor： CHOI, Kang Seuk ,  KO, Young Joon ,  NAH, Jin Ju ,  JO, Nam In

IPC: C12N15/79 ,  C12N15/86 ,  C12N5/16 ,  C12N15/09

CPC classification number: C12N7/00 ,  A61K2039/5258 ,  C12N2770/32323

Abstract: The present invention relates to a swine vesicular disease virus-like particle prepared by a gene recombination technique, as well as a preparation method thereof. More particularly, the invention relates to a method for preparing a swine vesicular disease virus-like particle, wherein the structural protein precursor (Pl) gene and 3CD protease gene of swine vesicular disease virus are inserted simultaneously into a baculovirus expression vector and are expressed in insect cells, so that the expressed 3CD protease enzyme digests the structural protein precursor into individual proteins which then form the capsid of swine vesicular disease virus by an self-assembly process.

Abstract translation: 本发明涉及通过基因重组技术制备的猪疱疹病毒样颗粒及其制备方法。 更具体地说，本发明涉及一种猪泡囊状病毒样颗粒的制备方法，其中将猪囊泡病病毒的结构蛋白前体（P1）基因和3CD蛋白酶基因同时插入杆状病毒表达载体中，并在 昆虫细胞，使得表达的3CD蛋白酶将结构蛋白前体消化成单独的蛋白质，然后通过自组装过程形成猪水疱病病毒的衣壳。

公开(公告)号：WO2014036645A1

公开(公告)日：2014-03-13

申请号：PCT/CA2013/050666

申请日：2013-08-29

Applicant: MEDICAGO INC.

Inventor： D'AOUST, Marc-Andre ,  LAVOIE, Pierre-Olivier ,  COUTURE, Manon ,  POULIN, Lucie ,  VEZINA, Louis-Philippe

IPC: C12N7/04 ,  A01H5/00 ,  C07K14/085 ,  C07K16/10 ,  C12N15/41 ,  C12N15/82 ,  C12N7/01

CPC classification number: C07K14/005 ,  A61K39/125 ,  A61K39/13 ,  C07K16/1009 ,  C07K2317/10 ,  C12N7/00 ,  C12N15/8258 ,  C12N2770/32322 ,  C12N2770/32323 ,  C12N2770/32351 ,  C12N2770/32623 ,  C12N2770/32634 ,  C12N2800/22

Abstract: A method of producing a picornavirus-like particle (PVLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, portion of the plant, or a plant cell. The first nucleic acid comprising a first regulaton region active in the plant operatively linked to a nucleotide sequence encoding a picornavims polypeptide. The second nucleic acid comprising a second regulaton region active in the plant and operationally linked to a nucleotide sequence encoding one or more picornavims protease. The plant, portion of the plant, or plant cell is incubated under conditions that permit the expression of the nucleic acids, thereby producing the PVLP. A PVLP comprising the polypeptide is also provided.

Abstract translation: 提供了一种在植物中生产小核糖核酸病毒样颗粒（PVLP）的方法。 该方法包括将第一核酸和第二核酸引入植物，植物部分或植物细胞中。 第一核酸包含在植物中有活性的第一调节区，其与编码小RNA聚糖多肽的核苷酸序列有效连接。 所述第二核酸包含在植物中有活性的第二调节区，并且与编码一种或多种微晶蛋白酶蛋白酶的核苷酸序列有效连接。 植物，植物部分或植物细胞在允许核酸表达的条件下温育，从而产生PVLP。 还提供了包含该多肽的PVLP。

公开(公告)号：WO2013098655A9

公开(公告)日：2013-12-19

申请号：PCT/IB2012003114

申请日：2012-11-01

Applicant: SENTINEXT THERAPEUTICS SDN BHD

Inventor： CARDOSA MARY JANE ,  JAMILUDDIN MOHAMAD FAKRUDDIN ,  HAMID SHARIFAH BINTI

IPC: A61K39/125 ,  A61K39/13 ,  A61K39/135

CPC classification number: A61K39/125 ,  A61K39/12 ,  A61K39/13 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/14043 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32351 ,  C12N2770/32371 ,  C12N2770/32634

Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.

Abstract translation: 本发明提供了用于生产源自小核糖核酸病毒科病毒成员的免疫活性抗原的材料和方法。 本发明的小核糖核酸病毒抗原可以以用作治疗性治疗中的受治疗者或预防小核糖核酸病毒感染的疫苗的形式。 本发明的小核糖核酸病毒抗原可以是用于疫苗的免疫原性组合物的形式，其被施用用于预防肠道病毒感染。 本发明进一步涵盖包含人肠道病毒A，人肠道病毒B，人肠道病毒C，人肠道病毒D抗原的免疫原性组合物及其在疫苗中用于预防肠道病毒感染的用途。

公开(公告)号：WO2004060912A2

公开(公告)日：2004-07-22

申请号：PCT/US2003/041567

申请日：2003-12-29

Applicant: UAB RESEARCH FOUNDATION ,  COSENZA, Larry

Inventor： COSENZA, Larry

IPC: C07K

CPC classification number: C12N15/86 ,  A61K48/00 ,  C12N15/85 ,  C12N2770/32322 ,  C12N2770/32323 ,  C12N2810/60 ,  C12N2820/55 ,  C12N2820/85 ,  C12N2830/00 ,  C12N2830/15 ,  C12N2830/55 ,  C12N2830/60

Abstract: The present invention encompasses chimeric capsid proteins, nucleic acids encoding such proteins and capsids containing chimeric capsid proteins. Methods of malting the chimeric capsid proteins, the nucleic acids that encode such proteins and capsids that contain chimeric capsid proteins are also encompassed within the scope of the invention. The invention further encompasses the use of the chimeric capsid proteins to produce protein elements and to present the elements for use in structure­-function studies, for use as therapeutic factors and for other purposes. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only.

Abstract translation: 本发明包括嵌合衣壳蛋白，编码这种蛋白质的核酸和含有嵌合衣壳蛋白的衣壳。 编码嵌合衣壳蛋白，编码这种蛋白质的核酸和含有嵌合衣壳蛋白的衣壳的方法也包括在本发明的范围内。 本发明还包括嵌合衣壳蛋白用于产生蛋白质元件并呈现用于结构功能研究的元件，用作治疗因素和用于其它目的的用途。 通过考虑本文公开的本发明的说明书和实践，本发明的其它实施例对于本领域技术人员将是显而易见的。 旨在将说明书和实施例视为仅作为示例。

公开(公告)号：WO2016019890A1

公开(公告)日：2016-02-11

申请号：PCT/CN2015/086264

申请日：2015-08-06

Applicant: MEDIGEN BIOTECHNOLOGY CORP.

Inventor： LIN, Young-Sun ,  CHENG, Jinyi ,  CHIANG, Ya-Lin ,  CHEN, Ming-Cheng ,  LAI, Kuei-Tai A. ,  YANG, Chih Ya

IPC: C07K19/00 ,  C07K14/005 ,  C07K14/02 ,  C12N15/09 ,  C07K14/08 ,  C12N7/00 ,  C12N5/10 ,  A61K39/12 ,  A61K47/48 ,  A61P31/14

CPC classification number: A61K39/292 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55572 ,  A61K2039/627 ,  A61K2039/645 ,  A61K2039/70 ,  C07K14/005 ,  C07K2319/40 ,  C12N7/00 ,  C12N2720/12323 ,  C12N2730/10123 ,  C12N2730/10134 ,  C12N2730/10151 ,  C12N2730/10171 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2770/16023 ,  C12N2770/16034 ,  C12N2770/16042 ,  C12N2770/16051 ,  C12N2770/16071 ,  C12N2770/28123 ,  C12N2770/28134 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32371 ,  Y02A50/467

Abstract: The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. The invention also relates to nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids. The invention further relates to pharmaceutical compositions comprising the dimeric fusion proteins and/or virus-like particles of the invention, and methods of prevention or treatment using such compositions.

Abstract translation: 本发明涉及包含这种二聚融合蛋白的二聚融合蛋白和病毒样颗粒。 这些二聚融合蛋白包含携带在两个病毒结构蛋白或其片段之间的抗原或抗原性片段，其具有或不具有接头，相对于传统的单体平台，使抗原或抗原片段和病毒结构蛋白之间的空间位阻最小化 或其片段。 这种新颖的设计提供了多价疫苗和增强的免疫原性。 本发明还涉及编码这种二聚融合蛋白的核酸和包含这种核酸的宿主细胞。 本发明还涉及包含本发明的二聚融合蛋白和/或病毒样颗粒的药物组合物，以及使用这种组合物的预防或治疗方法。

公开(公告)号：WO2015167710A1

公开(公告)日：2015-11-05

申请号：PCT/US2015/022738

申请日：2015-03-26

Applicant: NATIONAL HEALTH RESEARCH INSTITUTES ,  WANG, Lu-hai

Inventor： CHOW, Yen-hung ,  TSOU, Yueh-liang

IPC: A61K39/12 ,  A61K38/00

CPC classification number: A61K39/125 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/542 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/57 ,  C12N2710/10323 ,  C12N2710/10343 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32351 ,  C12N2770/32371 ,  Y02A50/466

Abstract: The present invention relates to a recombinant adenoviral vector for generating immunity against enterovirus infection. In one embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a PI protein and a 3 CD protease of an enterovirus. In another embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a 3C protease or a 3CD protease of an enterovirus. The present invention also relates to a vaccine composition comprising the recombinant adenoviral vector as described. A method of inducing an immune response in a subject against enterovirus infection using the recombinant adenoviral vector and the vaccine composition is provided. Further provided is a method for producing virus like particles of an enterovirus by expressing the adenoviral vector as described herein in mammalian cells.

Abstract translation: 本发明涉及用于产生针对肠道病毒感染的免疫的重组腺病毒载体。 在一个实施方案中，本发明的重组腺病毒载体包含编码肠道病毒的PI蛋白和3CD蛋白酶的表达盒。 在另一个实施方案中，本发明的重组腺病毒载体包含编码肠病毒的3C蛋白酶或3CD蛋白酶的表达盒。 本发明还涉及包含如上所述的重组腺病毒载体的疫苗组合物。 提供了使用重组腺病毒载体和疫苗组合物诱导受试者免疫应答的方法。 还提供了通过在哺乳动物细胞中表达本文所述的腺病毒载体来产生病毒样肠道病毒颗粒的方法。

公开(公告)号：WO2014183548A1

公开(公告)日：2014-11-20

申请号：PCT/CN2014/076240

申请日：2014-04-25

Applicant: 北京民海生物科技有限公司

Inventor： 顾美荣 ,  魏文进 ,  刘建凯 ,  宋琳琳 ,  许珊珊

IPC: C12N15/81 ,  C12N1/19 ,  A61K39/125 ,  A61P31/14 ,  C12N7/04 ,  C12R1/93 ,  C12R1/78

CPC classification number: A61K39/135 ,  A61K39/12 ,  A61K39/125 ,  A61K2039/5258 ,  A61K2039/55505 ,  C07K14/005 ,  C12N7/00 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32351

Abstract: 本发明提供了一种EV71病毒样颗粒及其制备方法与应用。通过将EV71病毒的P1蛋白基因和3CD蛋白酶基因与PMV质粒连接后构建PMV-P1-3CD重组表达质粒，然后转入汉逊酵母AU-0501表达菌株，得到AU-PMV-P1-3CD重组表达菌株；将重组表达菌株发酵培养和甲醇诱导表达EV71病毒样颗粒蛋白，离心收集菌体进行高压均浆破碎，上清液经离子交换层析、疏水层析、分子筛层析等纯化后获得EV71病毒样颗粒。